Pre Next

[1] LE Shijun?BAI Xue?HUANG Yuxi?WANG Wenxiao?GAO Huan?TANG Yuping,.Mechanism Research of Hydroxysafflower Yellow A in The Treatment of Cardiovascular and Cerebrovascular Diseases by Network pharmacology [J]. Journal of Shaanxi University of Traditional Chinese Medicine, 2021, 44(05): 106-112. [doi: 10.13424/j.cnki.jsctcm.2021.05.022]

Copy

Mechanism Research of Hydroxysafflower Yellow A in The Treatment of Cardiovascular and Cerebrovascular Diseases by Network pharmacology

Journal of Shaanxi University of Traditional Chinese Medicine[ISSN: 2096-1340/ CN: 61-1501/R] Volumes & Issues: 44 2021 05 pagination: 106-112 Column: Publication date: 2021-09-30

Article number:: 2096-1340(2021)05-0106-07

Author(s):: LE Shijun?BAI Xue?HUANG Yuxi?WANG Wenxiao?GAO Huan?TANG Yuping; Shaanxi University of Traditional Chinese Medicine,Shaanxi Xianyang 712046,China

Keywords:: Hydroxysafflower yellow A; Network pharmacology; Cardiovascular and cerebrovascular diseases; Action mechanism

ZTFLH:: R285

DOI:: 10.13424/j.cnki.jsctcm.2021.05.022

Code:: A

Abstract:: Objective To study the potential mechanism of hydroxysafflower yellow A (HSYA) in the treatment of cardiovascular and cerebrovascular diseases by network pharmacology.Methods By excavating the relevant literature on the treatment of cardiovascular and cerebrovascular diseases by HSYA in recent 10 years,the anti cardiovascular and cerebrovascular disease targets were collected,and then the biological information annotation database (DAVID) was used for go enrichment and KEGG pathway analysis.Finally,the “target-signal pathway” interactive network and topology analysis were constructed by Cytoscape 3.8.0 software.Results HSYA plays a role in the treatment of cardiovascular and cerebrovascular diseases by regulating 94 potential targets such as NFKB1 and RELA,intervening in important signal pathways such as fluid shear stress and atherosclerosis,TNF signal pathway,adipocytokine signal pathway and Apelin signal pathway.Conclusion This study preliminarily reveals the multidimensional regulatory network mechanism of HSYA in improving cardiovascular and cerebrovascular diseases from the perspective of network pharmacology,which provides a theoretical basis for its clinical application.

References:

［1］胡盛寿,高润霖,刘力生,等.《中国心血管病报告2018》概要［J］.中国循环杂志,2019,34(3)：209-220.
［2］Hao P,Jiang F,Chen Y,et al.Traditional Chinese medication for cardiovascular disease［J］.Nature Reviews Cardiology,2015,12(2)：115-122.
［3］唐梅森,龚后武,黄征德,等.冠心病血瘀证症状与药物组成最大频繁关联模式挖掘［J］.中国中西医结合杂志,2017,37(4)：492-494.
［4］Yue S,Tang Y,Li S,et al.Chemical and biological properties of quinochalcone Cglycosides from the florets of Carthamus tinctorius［J］.Molecules,2013,18 (12)：15220-15254.
［5］Lu Q,Xu J,Li Q,et al.Therapeutic efficacy and safety of safflower injection in the treatment of acute coronary syndrome［J］.EvidenceBased Complementary and Alternative Medicine,2021,Article ID：6617772.
［6］乐世俊,唐于平,王林艳,等.红花中黄酮类化合物的分离与体外抗氧化研究［J］.中国中药杂志,2014,39(17)：3295-3300.
［7］Meselhy MR,Kadota S,Momose Y,et al.Two new quinochalcone yellow pigments from Carthamus tinctorius and Ca2+ antagonistic activity of tinctormine［J］.Chemical & Pharmaceutical Bulletin,1993,41(10)：1796-1802.
［8］Hu MZ,Zhou ZY,Zhou ZY,et al.Effect and safety of hydroxysafflor yellow A for injection in patients with acute ischemic stroke of blood stasis syndrome：A phase II,multicenter,randomized,doubleblind,multipledose,activecontrolled clinical trial［J］.Chinese Journal of Integrative Medicine,2020,26：420-427.
［9］Tian JA controlled,doubleblind,randomized pilot clinical trial of hydroxysafflor yellow a on cognitive function in patients with vascular dementia［J］.Clinical Pharmacology & Therapeutics,2006,79(2)：44.
［10］李梢.网络药理学评价方法指南［J］.世界中医药,2021,16(4)：527-532.
［11］Yue SJ,Liu J,Feng WW,et al.System pharmacologybased dissection of the synergistic mechanism of Huangqi and Huanglian for diabetes mellitus［J］.Frontiers in Pharmacology,2017,8：694.
［12］李泮霖,苏薇薇.网络药理学在中药研究中的最新应用进展［J］.中草药,2016,47 (16)：2938-2942.
［13］Bai X,Wang WX,Fu RJ,et al.Therapeutic potential of hydroxysafflor yellow A on cardiocerebrovascular diseases［J］.Frontiers in Pharmacology,2020,11：01265.
［14］唐颖弘,戴君.活血化瘀类中成药在心脑血管疾病中的使用情况［J］.中医药管理杂志,2021,29 (2)：47-49.
［15］秦劭晨,梁伟雄,温晓文,等.注射用羟基红花黄色素A治疗急性缺血性中风血瘀证疗效观察［J］.中国实验方剂学杂志,2016,22 (21)：157-161.
［16］Xu H,Liu TL,Wang WJ,et al.Proteomic analysis of hydroxysafflor yellow A against cerebral ischemiareperfusion injury in rats［J］.Rejuvenation Research,2019,22：503-512.
［17］Yan K,Wang X,Pan H,et al.Safflower yellow and its main component HSYA alleviate dietinduced obesity in mice：Possible involvement of the increased antioxidant enzymes in liver and adipose tissue［J］.Frontiers in Pharmacology,2020,11：482.
［18］Lee M,Zhao H,Liu X,et al.Protective effect of hydroxysafflor yellow A on nephropathy by attenuating oxidative stress and inhibiting apoptosis in induced type 2 diabetes in rat［J］.Oxidative Medicine and Cellular Longevity,2020,,Article ID：7805393.
［19］Liu J,Yue SJ,Yang ZR,et al.Oral hydroxysafflor yellow A reduces obesity in mice by modulating the gut microbiota and serum metabolism［J］.Pharmacological Research,2018,134：40-50.
［20］Xi S,Zhang Q,Liu C,et al.Effects of hydroxy safflower yellowA on tumor capillary angiogenesis in transplanted human gastric adenocarcinoma BGC-823 tumors in nude mice［J］.Journal of Traditional Chinese Medicine,2012,32(2)：243-248.

Memo

基金项目：国家自然科学基金青年项目（81903786）；陕西省自然科学基金（2019JQ-054）；陕西中医药大学学科创新团队建设项目（2019-YL10）

Last Update: 2021-09-23